期刊
MOLECULAR THERAPY
卷 5, 期 3, 页码 233-241出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1006/mthe.2002.0545
关键词
gene therapy; readministration; adenovirus; DOTAP : chol; encapsulation; lung
资金
- NCI NIH HHS [CA 78792] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [R01CA078792] Funding Source: NIH RePORTER
Adenoviral vectors have been widely used for gene therapy, but they are limited both by the presence of a humoral immune response that dramatically decreases the level of transduction after reinjection and by their requirement for target cells to express appropriate receptors such as Coxsackie adenovirus receptor (CAR). To overcome both limits, we encapsulated adenovectors using bilamellar DOTAP:chol liposomes. Electron micrography (EM) showed that these liposomes efficiently encapsulated the vectors, allowing CAR-independent adenovector transduction of otherwise resistant cells. DOTAP:chol-encapsulated adenovectors encoding LacZ or alpha(1)-antitrypsin inhibitor (AAT) were also functionally resistant ex vivo and in vivo to the neutralizing effects of human anti-adenoviral antibodies, unlike other liposomal systems. Hence, bilamellar DOTAP:chol liposomes may be useful for applications using adenovectors in which the target cells lack adenoviral receptors or in which the recipient already has or develops a neutralizing antibody response that would otherwise inactivate readministered vector.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据